Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
August 8, 2025Open Access

Paroxysmal Nocturnal Hemoglobinuria: Unraveling Its Molecular Pathogenesis and Advancing Targeted Therapeutic Strategies

View Full Paper
Ask AI
Bookmark
Share

Authors

EAElisavet ApostolidouVGVasileios GeorgoulisDLDimitrios Leonardos

Discussion

Loading...

Member takes

Overview

This review highlights advances in complement inhibitors for paroxysmal nocturnal hemoglobinuria, addressing treatment challenges.

Key Points

  • Complement inhibitors significantly reduce thrombotic risk in patients with paroxysmal nocturnal hemoglobinuria, improving survival.
  • Eculizumab, the first approved C5 inhibitor, was effective but did not completely eliminate anemia caused by extravascular hemolysis.
  • Targeting proximal complement components has emerged as a promising therapeutic strategy for better management of PNH.
  • Ongoing challenges in treatment highlight the need for continued research and development of new therapeutic approaches.

Cite This Study

Apostolidou et al. (2025) studied this question.

synapsesocial.com/papers/68af2974cf1dd9ea359e2ef9https://doi.org/10.20944/preprints202508.0624.v1
View Full Paper
Ask AI
Bookmark
Share